Provide early detection, prognosis, and/or predicting response to available medications; develop new blood tests to better monitor treatment response; and, using blood-derived stem cells, test whether patients will be helped by emerging medication treatments.
Translate research into clinical care by defining patients who respond optimally to currently available and emerging therapies. Identify new therapeutic targets based on refined and granular understanding of disease mechanisms.
Worldwide, over 50 million people have dementia, and there are nearly 10 million new cases every year.
Researchers and clinicians at the Richman Center are collaborating to discover individualized therapeutics and diagnostics for earlier diagnosis and individualized interventions.
Exosomes can even travel easily from the brain to the blood, they have the unique potential to tell us what’s going on in the brain from just a blood sample. This innovation has the potential for developing biomarkers for AD diagnosis and therapeutics.
Collecting data from tens of thousands of patient medical records leverages the big data power analytics for leads in subtyping for diagnostics and therapeutics.
A unique personalized medicine approach involves the development of hiPSC models for the characterization of biologic subtypes of AD: from blood samples, brain cell lines can be individualized.
Which sub populations are more at-risk for cognitive decline and fast disease progression?
How can the current quality care be made available to all persons with dementia throughout Johns Hopkins?
How can we fast track the research from clinic to test tube and back to the clinic with biomarkers for subtyping and for advancing therapeutics?
How can existing brain MRI methods be refined for early detection, prognosis, or predicting response to available medications?
Can novel blood tests based on “exosomes” be used to learn about what’s going on in the brain so as to stage the AD brain disease and monitor treatment response?
Can blood derived stems cells be used to test whether individual patients will be helped by available and emerging medication treatments?
Hear from leading experts about ways to prevent the onset of dementia and memory disorders. (This panel was recorded May 12, 2022.)
Dr. Constantine Lyketsos presents the current medical knowledge and research to date on memory and Alzheimer's disease and answers frequently asked questions. ("What We Are Learning About Memory and Alzheimer's" was presented in April 10, 2021.)
The research we do directly impacts the treatment options available to our patients. Find out more about patient care for Alzheimer's Disease.
The Johns Hopkins Memory and Alzheimer's Treatment Center
The Johns Hopkins Bayview Medical Center
5300 Alpha Commons Drive, Floor 4
Baltimore, MD 21224
Dimitrios Kapogiannis, M.D. is Chief of the Human Neuroscience Unit at the National Institute of Aging and adjunct Associate Professor in the Department of Neurology at Johns Hopkins. He is a clinician-scientist, ABPN-certified in Neurology and UCNS-certified in Behavioral Neurology. His translational laboratory focuses on discovering novel biomarkers for preclinical diagnosis and therapeutic response in Alzheimer's and other neurodegenerative diseases. He has pioneered deriving Extracellular Vesicles enriched for neuronal and astrocytic origin from peripheral blood.
Kostas Lyketsos and his team are collecting data from tens of thousands of patient medical records, looking for demographic and genetic factors that determine how the disease progresses over time.